Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6 | P05231 | 8/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580647 | 0.93 | IL6 (0.63) | IL6RXFP1LMNAHPGDTSHR | |
| SCHEMBL4139194 | 0.92 | IL6 (0.64) | IL6MAPK1ALDH1A1 | |
| SCHEMBL4581423 | 0.91 | IL6 (0.63) | IL6APOBEC3AAPOBEC3GRXFP1TSHR | |
| SCHEMBL4140442 | 0.90 | IL6 (0.53) | IL6NPC1APOBEC3AAPOBEC3GMAPK1 | |
| SCHEMBL4139610 | 0.87 | IL6 (0.51) | IL6NPC1APOBEC3AAPOBEC3GALDH1A1 | |
| SCHEMBL4580531 | 0.87 | IL6 (0.62) | IL6RXFP1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL1917227 | 0.87 | IL6 (0.57) | IL6NPC1APOBEC3AAPOBEC3GRAB9A | |
| SCHEMBL4582014 | 0.87 | IL6 (0.66) | IL6LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4581415 | 0.86 | IL6 (0.72) | IL6APOBEC3AAPOBEC3GMAPK1LMNA | |
| SCHEMBL4581762 | 0.86 | IL6 (0.63) | IL6CCNT1CDK9LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975256-B2 | 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| US-8975256-B2 | 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| US-8975256-B2 | 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| US-20130303537-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUNDS HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8551991-B2 | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8551991-B2 | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-1995242-B1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-11-07 | — | — | EP | disclosed |
| EP-1995242-B1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-1995242-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-20080039433-A1 | Stabilized Tetracycline Compositions | SERENEX, INC. | 2008-02-14 | — | — | US | disclosed |
| WO-2007147133-A1 | STABILIZED TETRACYCLINE COMPOSITIONS | SERENEX, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1299351-A4 | NOVEL ARYL, ALKENYL, AND ALKYNL 4-DEDIMETHYLAMINOTETRACYCLINE DERIVATIVES | COLLAGENEX PHARM INC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1531830-A1 | METHOD FOR REDUCING C-RECTIVE PROTEIN LEVELS WITH NON-ANTIBACTERIAL TETRACYCLINE FORMULATIONS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004006938-A1 | METHOD FOR REDUCING C-RECTIVE PROTEIN LEVELS WITH NON-ANTIBACTERIAL TETRACYCLINE FORMULATIONS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1299351-A1 | NOVEL ARYL, ALKENYL, AND ALKYNL 4-DEDIMETHYLAMINOTETRACYCLINE DERIVATIVES | Collagenex Pharmaceuticals, Inc. (US) | 2003-04-09 | — | — | EP | disclosed |
| WO-2001087823-A1 | NOVEL ARYL, ALKENYL, AND ALKYNL 4-DEDIMETHYLAMINOTETRACYCLINE DERIVATIVES | COLLAGENEX PHARMACEUTICALS, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039433-A1 | Stabilized Tetracycline Compositions | MALT1, TREH, TET1 | IL6 49/4885NPC1 2645/4885APOBEC3A 2943/4885 |
| US-20130303537-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUNDS HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | NR3C1, NR3C2, NR5A1 | IL6 3798/4885NPC1 4406/4885APOBEC3A 4877/4885 |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | NR3C1, NR3C2, MC2R | IL6 3728/4885NPC1 4638/4885APOBEC3A 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.